Cambium Medical Technologies LLC   Report issue

For profit Phase 2
Founded: Atlanta GA United States (2013)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03414645
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Cambium Medical Technologies LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

platelet-rich plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Graft vs Host Disease (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1